TP53 and neoplasm: Studies have shown that TP53 mutations can enhance sensitivity to PD-1 inhibitors in two ways: first, mutations lead to DNA repair defects, significantly increasing tumor mutational burden (TMB), increasing neoantigen presentation, and activating T cell-mediated immune responses.